Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
3(38%)
Results Posted
100%(2 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_2
4
50%
Ph phase_1
4
50%

Phase Distribution

4

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
4(50.0%)
Phase 2Efficacy & side effects
4(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

3

trials recruiting

Total Trials

8

all time

Status Distribution
Active(4)
Completed(2)
Terminated(2)

Detailed Status

Recruiting3
Completed2
Enrolling by invitation1
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
3
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (50.0%)
Phase 24 (50.0%)

Trials by Status

completed225%
enrolling_by_invitation113%
recruiting338%
terminated113%
withdrawn113%

Recent Activity

3 active trials
Showing 5 of 8
recruitingphase_2

A Study of ZEN003694 in People With Squamous Cell Lung Cancer

NCT05607108
terminatedphase_2

A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer

NCT03901469
recruitingphase_2

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

NCT05071937
enrolling_by_invitationphase_1

Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol

NCT04145375
recruitingphase_2

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

NCT04986423
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT05607108Phase 2

A Study of ZEN003694 in People With Squamous Cell Lung Cancer

Recruiting
NCT03901469Phase 2

A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer

Terminated
NCT05071937Phase 2

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

Recruiting
NCT04145375Phase 1

Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol

Enrolling By Invitation
NCT04986423Phase 2

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

Recruiting
NCT06161493Phase 1

ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors

Withdrawn
NCT02711956Phase 1

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Completed
NCT02705469Phase 1

A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8